RESUMO
INTRODUCTION: Excessive visceral adiposity is known to drive the onset of metabolic derangements, mostly involving oxidative stress, prolonged inflammation, and cellular senescence. N-acetylcysteine (NAC) is a synthetic form of
Assuntos
Acetilcisteína , Senescência Celular , Inibidor de Quinase Dependente de Ciclina p21 , Interleucina-6 , Gordura Intra-Abdominal , Obesidade , Fator de Necrose Tumoral alfa , beta-Galactosidase , Humanos , Acetilcisteína/farmacologia , Gordura Intra-Abdominal/metabolismo , Gordura Intra-Abdominal/efeitos dos fármacos , Senescência Celular/efeitos dos fármacos , Adulto , Masculino , beta-Galactosidase/metabolismo , Interleucina-6/metabolismo , Fator de Necrose Tumoral alfa/metabolismo , Feminino , Obesidade/metabolismo , Obesidade/tratamento farmacológico , Inibidor de Quinase Dependente de Ciclina p21/metabolismo , Inibidor de Quinase Dependente de Ciclina p21/genética , Inibidor p16 de Quinase Dependente de Ciclina/metabolismo , Pessoa de Meia-Idade , Proteína Supressora de Tumor p53/metabolismo , Antioxidantes/farmacologia , Antioxidantes/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Inflamação/metabolismoRESUMO
Background: We decided to conduct this study with the aim of investigating the effects of N-Acetylcysteine (NAC) on obesity complications and senescence of visceral adipose tissue in obese adults. Methods and analysis: The present study was conducted as a randomized clinical trial (RCT) (Clinical trial registry number: IRCT20220727055563N1) on 40 obese adults candidates for bariatric surgery, who were randomly assigned to receive 600 mg of NAC (n = 20) or placebo as a control (n = 20) for 4 weeks. During bariatric surgery, visceral adipose tissue was used to examine gene expression and senescence cells using SA-ß-gal. Results: Our findings showed that intervention with NAC significantly reduces SA-ß-gal activity (as a marker of senescence) and expression of p16 and interleukin 6 (IL-6) genes in the visceral adipose tissue compared to placebo in obese adults for 4 weeks. In addition, our findings showed the potential and beneficial effect of NAC administration on reducing the levels of inflammatory factors including IL-6 and high-sensitivity C-reactive protein (hs-CRP), as well as the level of fasting blood sugar (FBS), homeostatic model assessment of insulin resistance (HOMA-IR), and insulin compared to placebo after adjusting for confounders. No significant effect was indicated on anthropometric factors and lipid profile. Conclusion: Findings showed that NAC, in addition to having a potential beneficial effect on reducing some of the complications caused by obesity, seems to have synolytic/senomorphic potential as well. Clinical trial registration: [https://clinicaltrials.gov/], identifier [IRCT20220727055563N1].